Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, Schäfer-Eckart K, Burgues JMB, Steffen B, Bernal T, Krause S, Riaza R, Schliemann C, Cervera J, Kaufmann M, Torres-Miñana L, Hänel M, Acuña-Cruz E, Jost E, Algarra JL, Crysandt M, Fransecky L, Cornago-Navascues J, Kraus S, Martinez-Lopez J, Einsele H, Niemann D, Neubauer A, Seggewiss-Bernhardt R, Scholl S, Klein SA, Schmid C, Schaich M, Schmidt-Hieber M, Zukunft S, Ho AD, Platzbecker U, Baldus CD, Müller-Tidow C, Thiede C, Bornhäuser M, Serve H, Levis MJ, Montesinos P, Röllig C, Schlenk RF (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Book Volume: 108

Pages Range: 34-41

Journal Issue: 1

DOI: 10.3324/haematol.2022.281137

Abstract

We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97 (78%) patients. Twenty-two (22%) and 15 (15%) of 101 tested patients harbored NPM1 and FLT3-ITD mutations. Two (3%) of 72 tested patients had double CEBPA mutations. Data on response to intensive anthracycline-based induction therapy were available for 119 patients. Complete remission was achieved in 67% (n=80) and the early death rate was 5% (n=6). Notably, patients with trisomy 4 as sole abnormality had a complete remission rate of 89%. Allogeneic hematopoietic cell transplantation was performed in 40 (34%) patients, of whom 19 were transplanted in first complete remission. The median follow-up of the intensively treated cohort was 5.76 years (95% confidence interval [95% CI]: 2.99-7.61 years). The 5-year overall survival and relapse-free survival rates were 30% (95% CI: 22-41%) and 27% (95% CI: 18-41%), respectively. An Andersen-Gill regression model on overall survival revealed that favorable-risk according to the European LeukemiaNet classification (hazard ratio [HR]=0.34; P=0.006) and trisomy 4 as sole abnormality (HR=0.41; P=0.01) were favorable factors, whereas age with a difference of 10 years (HR=1.15; P=0.11), female gender (HR=0.74; P=0.20) and allogeneic hematopoietic cell transplantation (HR=0.64; P=0.14) did not have an significant impact. In our cohort, patients with trisomy 4 as their sole abnormality had a high complete remission rate and favorable clinical outcome. Allogeneic hematopoietic cell transplantation did not seem to improve overall survival.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Central University Hospital of Asturias Spain (ES) Klinikum Nürnberg Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Sidney Kimmel Comprehensive Cancer Center (SKCCC) United States (USA) (US) Universitätsklinikum Essen Germany (DE) Universitätsklinikum Würzburg Germany (DE) Universitätsklinikum Leipzig Germany (DE) Sozialstiftung Bamberg Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Robert-Bosch-Krankenhaus Germany (DE) Universidad Complutense de Madrid (UCM) Spain (ES) Hospital Universitario y Politécnico de La Fe Spain (ES) Universitätsklinikum Münster Germany (DE) Universitätsklinikum Jena Germany (DE) Klinikum Chemnitz Germany (DE) Gemeinschaftsklinikum Mittelrhein Germany (DE) Hospital Universitario Severo Ochoa Spain (ES) Universität Augsburg Germany (DE) Rems-Murr-Kliniken Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Hospital General Universitario de Alicante Spain (ES) Hospital de São João / Saint John Hospital Portugal (PT) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Universitätsklinikum Mannheim Germany (DE) Hospital San Pedro de Alcántara Spain (ES) Carl-Thiem-Klinikum Germany (DE) Complejo Hospitalario Universitario de Albacete Spain (ES) Hospital Universitario Fundación Jiménez Díaz Spain (ES) Universitätsklinikum Gießen und Marburg (UKGM) Germany (DE)

How to cite

APA:

Kayser, S., Martínez-Cuadrón, D., Hanoun, M., Stölzel, F., Gil, C., Reinhardt, H.C.,... Schlenk, R.F. (2023). Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. Haematologica, 108(1), 34-41. https://doi.org/10.3324/haematol.2022.281137

MLA:

Kayser, Sabine, et al. "Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4." Haematologica 108.1 (2023): 34-41.

BibTeX: Download